These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

233 related items for PubMed ID: 26826383

  • 1. Cancer-associated fibroblasts attenuate Cisplatin-induced apoptosis in ovarian cancer cells by promoting STAT3 signaling.
    Yan H, Guo BY, Zhang S.
    Biochem Biophys Res Commun; 2016 Feb 19; 470(4):947-54. PubMed ID: 26826383
    [Abstract] [Full Text] [Related]

  • 2. Silencing of the STAT3 signaling pathway reverses the inherent and induced chemoresistance of human ovarian cancer cells.
    Han Z, Feng J, Hong Z, Chen L, Li W, Liao S, Wang X, Ji T, Wang S, Ma D, Chen G, Gao Q.
    Biochem Biophys Res Commun; 2013 May 31; 435(2):188-94. PubMed ID: 23665025
    [Abstract] [Full Text] [Related]

  • 3. A potent oncolytic adenovirus selectively blocks the STAT3 signaling pathway and potentiates cisplatin antitumor activity in ovarian cancer.
    Han Z, Hong Z, Gao Q, Chen C, Hao Z, Ji T, Hu W, Yan Y, Feng J, Liao S, Wu P, Wang D, Wang S, Zhou J, Ma D.
    Hum Gene Ther; 2012 Jan 31; 23(1):32-45. PubMed ID: 21875334
    [Abstract] [Full Text] [Related]

  • 4. Abrogation of constitutive Stat3 activity circumvents cisplatin resistant ovarian cancer.
    Ji T, Gong D, Han Z, Wei X, Yan Y, Ye F, Ding W, Wang J, Xia X, Li F, Hu W, Lu Y, Wang S, Zhou J, Ma D, Gao Q.
    Cancer Lett; 2013 Dec 01; 341(2):231-9. PubMed ID: 23962558
    [Abstract] [Full Text] [Related]

  • 5. Cisplatin-induced CCL5 secretion from CAFs promotes cisplatin-resistance in ovarian cancer via regulation of the STAT3 and PI3K/Akt signaling pathways.
    Zhou B, Sun C, Li N, Shan W, Lu H, Guo L, Guo E, Xia M, Weng D, Meng L, Hu J, Ma D, Chen G.
    Int J Oncol; 2016 May 01; 48(5):2087-97. PubMed ID: 26983899
    [Abstract] [Full Text] [Related]

  • 6. Cancer-associated fibroblasts treated with cisplatin facilitates chemoresistance of lung adenocarcinoma through IL-11/IL-11R/STAT3 signaling pathway.
    Tao L, Huang G, Wang R, Pan Y, He Z, Chu X, Song H, Chen L.
    Sci Rep; 2016 Dec 06; 6():38408. PubMed ID: 27922075
    [Abstract] [Full Text] [Related]

  • 7. Absence of Bcl-xL down-regulation in response to cisplatin is associated with chemoresistance in ovarian carcinoma cells.
    Villedieu M, Louis MH, Dutoit S, Brotin E, Lincet H, Duigou F, Staedel C, Gauduchon P, Poulain L.
    Gynecol Oncol; 2007 Apr 06; 105(1):31-44. PubMed ID: 17275076
    [Abstract] [Full Text] [Related]

  • 8. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
    Wang L, Zhang F, Cui JY, Chen L, Chen YT, Liu BW.
    Oncol Rep; 2018 May 06; 39(5):2081-2090. PubMed ID: 29565447
    [Abstract] [Full Text] [Related]

  • 9. Reversing chemoresistance in cisplatin-resistant human ovarian cancer cells: a role of c-Jun NH2-terminal kinase 1.
    Li F, Meng L, Zhou J, Xing H, Wang S, Xu G, Zhu H, Wang B, Chen G, Lu YP, Ma D.
    Biochem Biophys Res Commun; 2005 Oct 07; 335(4):1070-7. PubMed ID: 16105650
    [Abstract] [Full Text] [Related]

  • 10. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells.
    Yue P, Zhang X, Paladino D, Sengupta B, Ahmad S, Holloway RW, Ingersoll SB, Turkson J.
    Oncogene; 2012 May 03; 31(18):2309-22. PubMed ID: 21909139
    [Abstract] [Full Text] [Related]

  • 11. Signal transducers and activators of transcription 3 pathway activation in drug-resistant ovarian cancer.
    Duan Z, Foster R, Bell DA, Mahoney J, Wolak K, Vaidya A, Hampel C, Lee H, Seiden MV.
    Clin Cancer Res; 2006 Sep 01; 12(17):5055-63. PubMed ID: 16951221
    [Abstract] [Full Text] [Related]

  • 12. Early responses of the STAT3 pathway to platinum drugs are associated with cisplatin resistance in epithelial ovarian cancer.
    Sheng WJ, Jiang H, Wu DL, Zheng JH.
    Braz J Med Biol Res; 2013 Aug 01; 46(8):650-8. PubMed ID: 23969971
    [Abstract] [Full Text] [Related]

  • 13. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
    Wang Y, Li LZ, Ye L, Niu XL, Liu X, Zhu YQ, Sun WJ, Liang YJ.
    Zhonghua Fu Chan Ke Za Zhi; 2010 Sep 01; 45(9):691-8. PubMed ID: 21092551
    [Abstract] [Full Text] [Related]

  • 14. Leukotriene B4 receptor-2 contributes to chemoresistance of SK-OV-3 ovarian cancer cells through activation of signal transducer and activator of transcription-3-linked cascade.
    Park J, Park SY, Kim JH.
    Biochim Biophys Acta; 2016 Feb 01; 1863(2):236-43. PubMed ID: 26597704
    [Abstract] [Full Text] [Related]

  • 15. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells.
    Asselin E, Mills GB, Tsang BK.
    Cancer Res; 2001 Mar 01; 61(5):1862-8. PubMed ID: 11280739
    [Abstract] [Full Text] [Related]

  • 16. The cytoplasmic translocation of Cx32 mediates cisplatin resistance in ovarian cancer cells.
    Wu W, Fan L, Bao Z, Zhang Y, Peng Y, Shao M, Xiang Y, Zhang X, Wang Q, Tao L.
    Biochem Biophys Res Commun; 2017 May 27; 487(2):292-299. PubMed ID: 28412364
    [Abstract] [Full Text] [Related]

  • 17. Inhibitor of signal transducer and activator of transcription 3 (STAT3) suppresses ovarian cancer growth, migration and invasion and enhances the effect of cisplatin in vitro.
    Tang YJ, Sun ZL, Wu WG, Xing J, He YF, Xin DM, Han P.
    Genet Mol Res; 2015 Mar 30; 14(1):2450-60. PubMed ID: 25867391
    [Abstract] [Full Text] [Related]

  • 18. Small-molecule compounds targeting the STAT3 DNA-binding domain suppress survival of cisplatin-resistant human ovarian cancer cells by inducing apoptosis.
    Huang W, Liu Y, Wang J, Yuan X, Jin HW, Zhang LR, Zhang JT, Liu ZM, Cui JR.
    Eur J Med Chem; 2018 Sep 05; 157():887-897. PubMed ID: 30145375
    [Abstract] [Full Text] [Related]

  • 19. Cisplatin inhibits paclitaxel-induced apoptosis in cisplatin-resistant ovarian cancer cell lines: possible explanation for failure of combination therapy.
    Judson PL, Watson JM, Gehrig PA, Fowler WC, Haskill JS.
    Cancer Res; 1999 May 15; 59(10):2425-32. PubMed ID: 10344753
    [Abstract] [Full Text] [Related]

  • 20. Autocrine production of interleukin-6 confers cisplatin and paclitaxel resistance in ovarian cancer cells.
    Wang Y, Niu XL, Qu Y, Wu J, Zhu YQ, Sun WJ, Li LZ.
    Cancer Lett; 2010 Sep 01; 295(1):110-23. PubMed ID: 20236757
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.